Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib and Bevacizumab for Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Females that are at least 18 years of age.~* Women of childbearing potential must have a negative serum pregnancy test at screening.~* Documented evidence of HER2-overexpressing unresectable or metastatic breast cancer. Disease may/may not have been treated in metastatic setting.~* Subjects are permitted (but not required) to have previously-treated brain metastases that are stable and asymptomatic.~* Adequate hepatic, renal and cardiac function~* ECOG score 0-1 and a life expectancy of at least 12 weeks.~* Able to swallow oral medication~* Signed informed consent~Exclusion criteria:~* Pregnancy~* Unstable or symptomatic CNS metastases~* Major surgery within 28 days of enrollment (minor surgery within 7 days).~* Prior anti-cancer treatment within 14 days of enrollment, or unresolved treatment-related toxicities.~* A serious non-healing wound, ulcer, or bone fracture at baseline.~* Class II, III or IV heart failure as defined by the NYHA functional classification system~* History of significant vascular disease, arterial thrombosis, unstable INR, hypertensive crisis, or uncontrolled hypertension.~* History of myocardial infarction, stenting procedure, or angioplasty within 6 months of enrollment.~* History of abdominal fistulae, gastrointestinal perforation, or intra-abdominal abscess within 6 months of enrollment.~* History of malabsorption syndrome, ulcerative colitis, or bowel obstruction.~* Proteinuria~* Requires concurrent anti-cancer treatment or investigational treatment.~* Known hypersensitivity to either study medication~* Received investigational treatment within 28 days or 5 half-lives, whichever is longer~* Concurrent disease or circumstances that would lead the investigator would consider the subject an inappropriate candidate for the study~* Requires medication that has been excluded during study participation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral lapatinib tablets in combination with IV bevacizumab (Type: EXPERIMENTAL): 1500 mg oral lapatinib (once daily) plus 10 mg/kg intravenous bevacizumab (every two weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).